-+ 0.00%
-+ 0.00%
-+ 0.00%

BEAM THERAPEUTICS REPORTS INITIAL CLINICAL DATA FROM PHASE 1/2 TRIAL OF BEAM-301, DEMONSTRATING PROOF OF CONCEPT FOR GENETIC CORRECTION IN GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA) AT ESGCT 33RD ANNUAL CONGRESS

Reuters·10/27/2026 11:04:01

Veuillez vous connecter pour afficher les détails des actualités